United Therapeutics stock kpis
Want to see UTHR full AI Analyst Report?
Revenue by Segment
Separates income from core drug sales, services, licensing, and any organ- or device-related activities to show which parts of the business drive profit and growth. High concentration in a small number of therapies raises patent and competition risk, while a rising share from newer products, services, or recurring programs signals diversification and potential margin improvement.
Tyvaso remains the clear revenue engine—its multi‑year climb has slowed and recently flattened amid competitive pressure even as starts/referrals and patient counts hit records; management doubled the sales force and pushed major filings (Tyvaso IPF sNDA, ralinepag NDA), so 2027 approvals could drive a material upside and justify the narrowed path to a ~$4B run‑rate. Legacy drugs (Remodulin, Orenitram, Unituxin) supply a stable base, but near‑term revenue is uncertain given sales lag versus patient metrics and peer uptake risk.
UTHR Revenue by Segment
| Date | Other | Tyvaso | Remodulin | Orenitram | Unituxin | Adcirca |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | $4.90M | $503.80M | $122.00M | $145.00M | $52.30M | $4.50M |
| Jun 30, 2026 | $6.80M | $452.60M | $126.30M | $125.70M | $65.20M | $6.70M |
| Mar 31, 2026 | $5.30M | $457.50M | $126.60M | $135.60M | $53.60M | $2.90M |
| Dec 31, 2025 | $6.60M | $464.30M | $128.00M | $121.20M | $62.30M | $7.80M |
| Sep 30, 2025 | $6.90M | $478.00M | $125.90M | $131.10M | $47.90M | $9.70M |
| Jun 30, 2025 | $5.50M | $469.60M | $134.70M | $123.90M | $58.40M | $6.50M |
| Mar 31, 2025 | $5.00M | $466.30M | $138.20M | $120.70M | $58.20M | $6.00M |
| Dec 31, 2024 | $5.50M | $415.90M | $134.50M | $107.80M | $67.50M | $4.70M |
| Sep 30, 2024 | $5.50M | $433.80M | $128.30M | $113.20M | $61.10M | $7.00M |
| Jun 30, 2024 | $4.90M | $398.20M | $147.30M | $107.10M | $51.70M | $5.70M |
| Mar 31, 2024 | $6.20M | $372.50M | $128.00M | $106.20M | $58.40M | $6.40M |
| Dec 31, 2023 | $3.90M | $350.60M | $115.10M | $84.10M | $54.20M | $6.80M |
| Sep 30, 2023 | $1.90M | $325.80M | $131.10M | $92.00M | $51.30M | $7.30M |
| Jun 30, 2023 | $0.00 | $318.90M | $127.20M | $95.10M | $44.30M | $7.50M |
| Mar 31, 2023 | $2.50M | $238.40M | $121.40M | $88.20M | $49.10M | $7.30M |
| Dec 31, 2022 | $3.80M | $242.30M | $122.50M | $75.80M | $36.70M | $10.40M |
| Sep 30, 2022 | $0.00 | $257.70M | $114.00M | $87.50M | $46.10M | $10.70M |
| Jun 30, 2022 | $0.00 | $201.00M | $132.00M | $79.00M | $44.50M | $10.40M |
| Mar 31, 2022 | $10.00M | $172.00M | $131.70M | $82.80M | $55.60M | $9.80M |
| Dec 31, 2021 | $0.00 | $166.50M | $118.30M | $72.30M | $50.00M | $8.10M |
| Sep 30, 2021 | $0.00 | $164.20M | $125.40M | $85.20M | $55.30M | $14.60M |
| Jun 30, 2021 | $0.00 | $153.80M | $139.80M | $76.20M | $53.10M | $23.60M |
| Mar 31, 2021 | $0.00 | $123.00M | $130.20M | $72.40M | $43.90M | $9.60M |
| Dec 31, 2020 | $0.00 | $131.70M | $127.90M | $74.00M | $29.70M | $21.60M |
| Sep 30, 2020 | $0.00 | $129.50M | $124.50M | $74.70M | $37.60M | $13.80M |
| Jun 30, 2020 | $0.00 | $119.20M | $119.00M | $75.40M | $29.00M | $19.40M |
| Mar 31, 2020 | $0.00 | $102.90M | $145.30M | $69.00M | $26.60M | $12.50M |
| Dec 31, 2019 | $0.00 | $91.40M | $107.40M | $50.90M | $33.60M | $27.80M |
